Acumen Pharmaceuticals Stock (NASDAQ:ABOS)
Previous Close
$2.45
52W Range
$1.81 - $5.65
50D Avg
$2.79
200D Avg
$3.23
Market Cap
$156.21M
Avg Vol (3M)
$403.55K
Beta
0.08
Div Yield
-
ABOS Company Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.